Latest Operational Cash Flow News

MEC Resources has successfully completed a $2.65 million entitlement offer and resumed trading on the ASX after nearly five years of suspension. The company is now focused on advancing its energy investments, including navigating ongoing legal issues with its Advent Energy joint venture.

PARKD Ltd reports substantial structural completions on flagship projects and positive operating cash flow in Q2 FY25, setting the stage for licensing negotiations with Fielders.

Bioxyne Limited has reported a remarkable 77% jump in revenue for Q2 FY2025, alongside positive operating cash flow, as it prepares to expand manufacturing capacity and enter new international markets.

Resonance Health has reported record quarterly customer receipts of $5 million, a 57% increase from the previous quarter, alongside a major $13.8 million clinical trial contract win, signaling robust growth across its healthcare technology and clinical trial services.

Bowen Coking Coal reported a strong December quarter with record coal sales and a 39% reduction in cash costs, underpinning a $29 million EBITDA despite softer coal prices.

Energy Resources of Australia Limited reported a substantial net cash outflow of $183.9 million in Q4 2024, driven by significant rehabilitation payments, while raising $766.5 million through equity to bolster its cash position.

Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.

A1 Investments & Resources Ltd reported minimal cash flow activity for the December 2023 quarter while actively pursuing renewable energy acquisition opportunities in Japan and Australia.

Felix Group Holdings has reported a second consecutive quarter of positive operating cash flow alongside strong customer acquisition and contract expansions, notably within the mining and resources sector.

De.mem Limited has delivered its second highest quarterly cash receipts ever alongside positive operating cash flow for the December 2024 quarter, marking a milestone full-year cash flow turnaround and setting the stage for continued growth in 2025.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Vection Technologies has reported a milestone positive net cash flow in its traditionally weak quarter, driven by a 60% half-on-half revenue surge and strategic acquisition integration.